Image

Objective Assessment of Intraocular Lens Tilt and Decentration

Objective Assessment of Intraocular Lens Tilt and Decentration

Recruiting
22 years and older
All
Phase N/A

Powered by AI

Overview

Prospective, multi-center, non-interventional, open label, randomized clinical study.

Description

The objective of this study is to evaluate the repeatability and reproducibility (R\&R) of a method based on Optical Coherence Tomography (OCT) image analysis for assessing IOL tilt and decentration in patients unilaterally or bilaterally implanted with TECNIS refractive or diffractive non-toric IOL models.

Eligibility

INCLUSION CRITERIA (ALL CRITERIA APPLY TO STUDY EYE)

  1. Read, understand, and sign the informed consent and HIPAA authorization forms, and receive a fully executed copy of the signed forms.
  2. Appear capable and willing to adhere to the clinical protocol instructions.
  3. Be 22 years of age or older at the time of screening.
  4. Have undergone unilateral or bilateral implantation with a desired non-toric TECNIS IOL design (e.g., refractive or diffractive).
  5. At least three months postoperative in the eligible eye.

EXCLUSION CRITERIA (ALL CRITERIA APPLY TO STUDY EYE)

  1. Any medical or ocular history, in the opinion of the investigator, that may impact study procedures such as ocular trauma, pseudoexfoliation syndrome, retinal pigment degeneration, macular pathology, glaucoma, retinal disease, corneal disease, or corneal opacities.
  2. Have any condition that may affect the eye's ability to fixate (e.g., amblyopia).
  3. Have a history of corneal or intraocular surgery other than cataract surgery.
  4. Using ocular or systemic medications known to interact with dilation drops.
  5. Have a history of allergic reactions to dilation drops.
  6. Have clinically significant pupil abnormalities (e.g., non-reactive, fixed, or abnormally shaped pupils).
  7. Has an intraocular pressure of ≥ 21mm Hg before mydriasis.
  8. Have a mydriatic pupil diameter of less than 6 mm.
  9. Have participated in a clinical trial within 7 days prior to study enrollment.
  10. An employee (e.g., Investigator, Coordinator, or Technician) or immediate family member (including partner, child, parent, grandparent, grandchild, or sibling) of an employee of the clinical site or study sponsor.
  11. Currently pregnant or lactating.

Study details
    Tilt and Decentration

NCT07324200

Johnson & Johnson Surgical Vision, Inc.

13 May 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.